# Formulations Inteded to Deter Manipulation
Also known as *abuse-deterrant formulations (ADFs)*, these medicines are generally engineered to be difficult to crush or have other aversion properties that deter consumption in ways other than intended. Pharmaceutical deterrence strategies include physical and chemical barriers, agonist/antagonist, aversion, prodrug, and drug delivery systems ([Table 1-2 for overview](https://www.painphysicianjournal.com/current/pdf?article=NDcxMA%3D%3D&journal=108)).<br>
_____

[Detailed study overview](https://www.opioiddata.org/studies/counfounding-opioid-safety-studies/) at the full project site [OpioidData.org](https://www.opioiddata.org)
<br>
See [FDA Guidance](https://www.fda.gov/media/84819/download) on evaluation of abuse-deterrent formulations for eligibility criteria for labeling.
<br>
_____

##### **Full list of NDCs for abuse-deterrent formulations of opioids for analytic purposes can be found [here](ADF_NDCs.csv)**

_____

This document contains information on abuse-deterrent formulations (ADF) of opioids.
_____

### Abuse-Deterrent Formulations - Approved

|Drug Name|NDA#|[Categories of Evidence](https://www.fda.gov/media/84819/download)|Intended Route of Deterrence|Documentation|Status|ER/IR|Approved as ADF?|
|---|---|-----------|---------|--------|---|---|---|
|OxyContin|22-272|Categories 1-3, Category 4 possible|Intravenous, intranasal|[Drugs@FDA: OxyContin](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022272)<br><br>[FDA AdCom: September 10-11, 2020](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-10-11-2020-joint-meeting-drug-safety-and-risk-management-advisory-committee-and-anesthetic#event-materials)<br><br>[OxyContin NDCs](OxyContin/oxycontin_NDCs.csv)<br><br>[OxyContin Documentation](OxyContin)|Active|ER|Yes|
|Hysingla ER|206627|**Intranasal & oral:** Category 1, Category 3<br>**Injection:** Category 1|Intravenous, intranasal, oral|[Drugs@FDA: Hysingla ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206627)<br><br>[Hysingla NDCs](Hysingla_ER/hysingla_NDCs.csv)<br><br>[Hysingla Documentation](Hysingla_ER)|Active|ER|Yes|
|MorphaBond ER|206544|**Injection:** Category 1<br>**Intranasal:** Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: MorphaBond ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206544)<br><br>[MorphaBond NDCs](MorphaBond_ER/morphabond_NDCs.csv)<br><br>[MorphaBond Documentation](MorphaBond_ER)|Discontinued|ER|Yes|
|Xtampza ER|208090|Categories 1-3|Intravenous, intranasal, oral|[Drugs@FDA: Xtampza ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208090)<br><br>FDA AdCom: September 11, [2015](https://wayback.archive-it.org/7993/20170403223626/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm433361.htm)<br><br>[Xtampza NDCs](Xtampza_ER/xtampza_NDCs.csv)<br><br>[Xtampza Documentation](Xtampza)|Active|ER|Yes|
|RoxyBond|209777|Categories 1-3|Intravenous, intranasal|[Drugs@FDA: RoxyBond](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209777)<br><br>FDA AdCom: April 5, [2017](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[RoxyBond Documentation](RoxyBond)|Discontinued|IR|Yes: Intravenous, intranasal|
|Embeda|022321|**Oral & Intranasal:** Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Embeda](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022321)<br><br>[Embeda NDCs](Embeda/embeda_NDCs.csv)<br><br>[Embeda Documentation](Embeda)|Discontinued|ER|Yes|
|Arymo ER|208603|Categories 1-3|Oral, intravenous, intranasal|[Drugs@FDA: Arymo ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208603)<br><br>FDA AdCom: August 4, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Arymo NDCs](Arymo_ER/arymo_NDCs.csv)<br><br>[Arymo Documentation](Arymo)|Discontinued|ER|Yes: Oral, intravenous, intranasal|
|Targiniq|205777|Category 1, Category 3|Intravenous, intranasal|[Drugs@FDA: Targiniq](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205777)<br><br>[Targiniq Documentation](Targiniq)|Discontinued|ER|Yes|
|Troxyca ER|207621|Category 1, Category 2, Category 3|Oral, intranasal|[Drugs@FDA: Troxyca ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207621)<br><br>FDA AdCom: June 8, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Troxyca Documentation](Troxyca)|Discontinued|ER|Yes:Oral, intranasal, intravenous|
|Vantrela ER|207975|Categories 1-3|Oral, intranasal, intravenous|[Drugs@FDA: Vantrela ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207975)<br><br>FDA AdCom: June 7, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Vantrela ER Documentation](Vantrela_ER)|Inactive|ER|Yes: Oral, intranasal, intravenous|

_____


### Abuse-Deterrent Formulations - Unsuccessful Applications

|Drug Name|NDA#|Categories of Evidence|Intended Route of Deterrence|Documentation|Status|ER/IR|Approved as ADF?|
|---|---|-----------|---------|--------|---|---|---|
|Oxaydo/Oxecta|202080|Category 3|Intranasal|[Drugs@FDA: Oxaydo](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202080)<br><br>[Oxaydo/Oxecta NDCs](Oxaydo/oxaydo_NDCs.csv)<br><br>[Oxaydo Documentation](Unsuccessful_applications/Oxaydo)|Active|IR|No|
|Oxycodone HCl ER with blue dye (Aximris XR)|209653|Categories 1-3|Oral, intravenous, intranasal|[FDA AdCom: January 15, 2020](https://www.fda.gov/advisory-committees/advisory-committee-calendar/january-15-2020-joint-meeting-anesthetic-and-analgesic-drug-products-advisory-committee-and-drug)<br><br>FDA AdCom: July 26, [2017](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Aximris XR Documentation](Unsuccessful_applications/Aximris_XR)|Inactive|ER|No|
|Opana ER|201655|Categories 1-4|Intranasal, intravenous|[Drugs@FDA: Opana ER](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201655)<br><br>FDA AdCom: March 13-14, [2020](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2017-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Opana Documentation](Unsuccessful_applications/Opana_ER)|Inactive|ER|No|
|Apadaz|208653|Categories 1-3|Oral, intranasal, intravenous, smoking|[Drugs@FDA: Apadaz](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208653)<br><br>FDA AdCom: May 5, [2016](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2016-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Apadaz Documentation](Unsuccessful_applications/Apadaz)|Inactive|IR|No|
|Remoxy ER|22324|Categories 1-3|Intranasal, intravenous, smoking|FDA AdCom: June 26, [2018](https://www.fda.gov/advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee/2018-meeting-materials-anesthetic-and-analgesic-drug-products-advisory-committee)<br><br>[Remoxy ER Documentation](Unsuccessful_applications/Remoxy_ER)|Inactive|ER|No|
|Avridi|206830|Categories 1-3|Intranasal, intravenous|FDA AdCom: September 10, [2015](https://wayback.archive-it.org/7993/20170403223626/https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/ucm433361.htm)<br><br>[Avridi Documentation](Unsuccessful_applications/Avridi)|Inactive|IR|No|
